The largest real-world cohort study of individuals with malignant pleural mesothelioma (MPM) found a median survival duration of 8 months regardless of whether patients received first-line treatment with cisplatin-based chemotherapy […] Read more
Treating the whole patient, not just the disease, is a basic tenet of holistic care. Understanding the physical, emotional, and spiritual needs of patients can help providers provide optimal care […] Read more
A significant number of patients with lung cancer did not undergo testing for all relevant biomarkers, according to real-world data from a study in Japan (MA08.08), and use of simultaneous […] Read more
While checkpoint inhibitors have improved the outlook for patients with advanced NSCLC, more information is needed about the long-term toxicities caused by the drugs and how they should be managed. […] Read more
The randomized phase III ADAURA trial stirred up considerable excitement last year when results from an unplanned interim analysis revealed an 80% reduction in the risk of disease recurrence or […] Read more
The social and emotional needs of patients are increasingly being recognized as equally important to their physical needs, and use of multidisciplinary teams is helping to bridge the gaps between […] Read more
Historically, sexual minorities have been underserved in the healthcare setting. Members of this patient population may be less likely to receive optimal care, especially when it comes to preventive care […] Read more
Although the initial research into adoptive T-cell therapy for solid tumors was related to tumor-infiltrating lymphocytes, there is a growing interest in the use of adoptive T-cell therapy for the […] Read more
With no approved treatments for advanced NSCLC with EGFR exon 20 insertion mutations, treatment is mainly limited to chemotherapy, as these cancers don’t respond to traditional tyrosine kinase inhibitors (TKIs). […] Read more
The results of one phase II study looking at PET/CT-guided adaptive radiation therapy and one PET boost trial in locally advanced NSCLC were presented in an Oral Abstract Session (OA2). […] Read more